Hot Features
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company’s LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic... Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company’s LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an oral formulation of amphotericin B that is starting Phase 3 clinical trials for the treatment of aspergillosis and cryptococcosis, as well as prevention of invasive fungal infections in patients due to immunosuppressive therapy. It offers MAT2501, an orally administered formulation of amikacin. The company was incorporated in 2013 and is based in Bedminster, New Jersey. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.1992 | -23.7425506555 | 0.839 | 0.839 | 0.5805 | 63401 | 0.73641848 | CS |
| 4 | 0.0503 | 8.5326547922 | 0.5895 | 0.8811 | 0.58 | 74901 | 0.76817773 | CS |
| 12 | 0.0591 | 10.1773721371 | 0.5807 | 0.8811 | 0.48 | 158873 | 0.59446041 | CS |
| 26 | -0.0902 | -12.3561643836 | 0.73 | 0.8811 | 0.48 | 90092 | 0.60273447 | CS |
| 52 | -0.2602 | -28.9111111111 | 0.9 | 3.09 | 0.48 | 179649 | 1.70003983 | CS |
| 156 | 0.2242 | 53.9461020212 | 0.4156 | 4.49 | 0.09 | 1266361 | 0.49040485 | CS |
| 260 | -0.2302 | -26.4597701149 | 0.87 | 4.49 | 0.09 | 1078788 | 0.61401533 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.